Plasma collection for production of Tromplate®, a hyperimmune anti-HPA-1a for the prevention of foetal and neonatal alloimmune thrombocytopenia

Aim: Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) is a rare but potentially very serious condition that occurs in about 1 out of 2000 pregnancies. The condition is characterized by destruction of the platelets of the foetus or newborn due to maternal alloantibodies most commonly directed to the Human Platelet Antigen 1a (HPA-1a). The foetus or newborn becomes thrombocytopenic and is at risk of intracranial haemorrhage, which may result in lifelong disability or death. Currently no satisfactory preventive treatment exists for this rare but potentially life-threatening condition. The PROFNAIT consortium is…